-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
About 2%-3% of colorectal cancer patients have detected HER2 gene amplification , although there is currently no HER2 targeted therapy drug approved for colorectal cancer.
About 2%-3% of colorectal cancer patients have detected HER2 gene amplification colorectal cancer
The DESTINY-CRC01 study aims to evaluate the efficacy of trastuzumab drutecan in patients with metastatic colorectal cancer with positive HER2 expression .
To evaluate the efficacy of trastuzumab drutecan in patients with metastatic colorectal cancer with positive HER2 expression
The DESTINY-CRC01 study is an open-label Phase 2 trial that recruited people aged 18 years or older (20 years old in Japan), EOCG 0-1 points, carrying RAS and BRAF V600E from 25 clinics and hospitals in multiple countries Wild-type, HER2-positive metastatic colorectal cancer patients who have progressed after second-line or multiple-line therapy.
immunity
The test patient received trastuzumab drutecan 6.
From February 23, 2018 to July 3, 2019, 78 patients (53, 7 and 18 in cohorts A, B, and C, respectively) were recruited , all of whom received at least one dose of study drug.
78 patients (53, 7 and 18 in cohorts A, B, and C, respectively)
Anti-tumor activity of trastuzumab drutecan
Anti-tumor activity of trastuzumab drutecanAfter a median follow-up of 27.
After a median follow-up of 27.
Progression-free survival and overall survival
Progression-free survival and overall survivalThe adverse reactions of grade 3 and above requiring emergency treatment that occurred in at least 10% of patients were neutropenia (22%) and anemia (14%).
In summary, trastuzumab drutecan has shown encouraging and persistent activity in patients with HER2-positive metastatic colorectal cancer refractory to standard treatment , and its safety is as previously reported.
Trastuzumab drutecan has shown encouraging persistent activity in patients with HER2-positive metastatic colorectal cancer refractory to standard treatment Encouraging persistent activity in refractory HER2-positive metastatic colorectal cancer patients
Original source:
Original source:Salvatore Siena, et al.
org/10.
1016/S1470-2045(21)00086-3" target="_blank" rel="noopener">Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
in this message
